Travere Therapeutics (TVTX) Reiterated at Hold by Stifel After FDA Asks for More Info
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Hold rating and $31.00 price target on Travere Therapeutics (NASDAQ: TVTX).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
